GW Succeeding With Cannabinoid Drug This Time Around
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug candidates targeting the cannabinoid receptors have a spotty past, so GW's successful Phase III data in pediatric epilepsy meets with great investor enthusiasm.